Key points from article :
Former NeuroPhage Pharmaceuticals changed its name to Proclara Biosciences.
Relaunches as clinical-stage company with lead program in Alzheimer’s, and earlier programs in multiple protein misfolding disorders.
Secured $47 million in Series E financing to develop candidates for Alzheimer’s, Parkinson’s and other diseases.
Initiated a Phase 1b clinical trial of its lead product candidate, NPT088, for Alzheimer’s disease.
Financing will support clinical development of NPT088, as well as the preclinical advancement of additional molecules.
Proclara has raised more than $110 million to date.
GAIM platform targets multiple misfolded proteins simultaneously, which may address multi-factorial diseases.
“..continued support of our investors speaks to the strength of our science and the tremendous potential for our therapies,” said Franz Hefti, president and CEO of Proclara.
